ES2928396T3 - Análogos deuterados de etifoxina, sus derivados y usos de los mismos - Google Patents
Análogos deuterados de etifoxina, sus derivados y usos de los mismos Download PDFInfo
- Publication number
- ES2928396T3 ES2928396T3 ES16769437T ES16769437T ES2928396T3 ES 2928396 T3 ES2928396 T3 ES 2928396T3 ES 16769437 T ES16769437 T ES 16769437T ES 16769437 T ES16769437 T ES 16769437T ES 2928396 T3 ES2928396 T3 ES 2928396T3
- Authority
- ES
- Spain
- Prior art keywords
- disorder
- compound
- disease
- etifoxine
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135979P | 2015-03-20 | 2015-03-20 | |
| PCT/US2016/023231 WO2016154039A1 (en) | 2015-03-20 | 2016-03-18 | Deuterated analogs of etifoxine, their derivatives and uses therof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2928396T3 true ES2928396T3 (es) | 2022-11-17 |
Family
ID=56977741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16769437T Active ES2928396T3 (es) | 2015-03-20 | 2016-03-18 | Análogos deuterados de etifoxina, sus derivados y usos de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10080755B2 (enExample) |
| EP (1) | EP3347006B1 (enExample) |
| JP (3) | JP6762507B2 (enExample) |
| KR (1) | KR102290766B1 (enExample) |
| CN (1) | CN107530323B (enExample) |
| AU (2) | AU2016235495B2 (enExample) |
| BR (1) | BR112017020081B1 (enExample) |
| CA (1) | CA2979853C (enExample) |
| DK (1) | DK3347006T3 (enExample) |
| ES (1) | ES2928396T3 (enExample) |
| HR (1) | HRP20221240T1 (enExample) |
| HU (1) | HUE060240T2 (enExample) |
| IL (2) | IL270627B2 (enExample) |
| LT (1) | LT3347006T (enExample) |
| MX (1) | MX383647B (enExample) |
| PL (1) | PL3347006T3 (enExample) |
| PT (1) | PT3347006T (enExample) |
| RS (1) | RS63654B1 (enExample) |
| SI (1) | SI3347006T1 (enExample) |
| SM (1) | SMT202200407T1 (enExample) |
| WO (1) | WO2016154039A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3347006B1 (en) * | 2015-03-20 | 2022-07-27 | GABA Therapeutics Inc. | Deuterated analogs of etifoxine, their derivatives and uses therof |
| US10420773B2 (en) * | 2017-09-26 | 2019-09-24 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with etifoxine |
| JP2021519276A (ja) * | 2018-03-23 | 2021-08-10 | コンサート ファーマシューティカルズ インコーポレイテッド | Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用 |
| EP3781264A4 (en) * | 2018-05-18 | 2021-06-16 | Ovid Therapeutics Inc. | METHODS FOR TREATING A HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT |
| CN112125862A (zh) * | 2019-06-25 | 2020-12-25 | 上海安谱实验科技股份有限公司 | 一种稳定同位素标记的阿特拉津-d5及其合成方法 |
| WO2021097427A1 (en) | 2019-11-15 | 2021-05-20 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
| US20240383942A1 (en) * | 2021-09-14 | 2024-11-21 | Nanjing Minova Pharmaceutical Co., Ltd. | Water-soluble allopregnanolone derivative, and preparation method therefor and use thereof |
| WO2023218251A1 (en) * | 2022-05-10 | 2023-11-16 | Clearsynth Labs Limied | Novel deuterium-enriched nefazodone analogues and method for preparing thereof |
| CN120390643A (zh) * | 2022-10-24 | 2025-07-29 | 加巴疗法股份有限公司 | 艾替伏辛的氘代类似物及施用而没有代谢自身诱导的方法 |
| AU2024366024B2 (en) * | 2023-10-23 | 2026-07-09 | Glomesh Intl Pty Ltd | A module for mounting items |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670772C3 (de) | 1966-11-24 | 1978-04-20 | Hoechst Ag, 6000 Frankfurt | 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate |
| FR2888748B1 (fr) | 2005-07-19 | 2007-10-12 | Biocodex | Composes neuroprotecteurs et compositions pharmaceutiques les comprenant |
| US20080039453A1 (en) * | 2006-03-20 | 2008-02-14 | David Putman | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use |
| CA2646007A1 (en) * | 2006-03-20 | 2007-09-27 | Xytis Inc. | Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use |
| JP2011001308A (ja) * | 2009-06-19 | 2011-01-06 | Research Foundation Itsuu Laboratory | 重水素化カルボスチリル化合物 |
| AU2011274496B2 (en) * | 2010-07-09 | 2016-03-10 | Teva Pharmaceutical Industries Ltd. | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| EP2730559A4 (en) * | 2011-07-05 | 2015-03-04 | Kemphys Ltd | DEUTERATED PHENYLPROPIONIC ACID DERIVATIVE |
| FR3016881B1 (fr) | 2014-01-29 | 2016-03-04 | Biocodex | Traitement des degenerescences et des lesions photo-induites de la retine |
| EP3347006B1 (en) * | 2015-03-20 | 2022-07-27 | GABA Therapeutics Inc. | Deuterated analogs of etifoxine, their derivatives and uses therof |
-
2016
- 2016-03-18 EP EP16769437.1A patent/EP3347006B1/en active Active
- 2016-03-18 PL PL16769437.1T patent/PL3347006T3/pl unknown
- 2016-03-18 LT LTEPPCT/US2016/023231T patent/LT3347006T/lt unknown
- 2016-03-18 JP JP2018500276A patent/JP6762507B2/ja active Active
- 2016-03-18 BR BR112017020081-3A patent/BR112017020081B1/pt active IP Right Grant
- 2016-03-18 IL IL270627A patent/IL270627B2/en unknown
- 2016-03-18 KR KR1020177028263A patent/KR102290766B1/ko active Active
- 2016-03-18 RS RS20220948A patent/RS63654B1/sr unknown
- 2016-03-18 US US15/557,748 patent/US10080755B2/en active Active
- 2016-03-18 PT PT167694371T patent/PT3347006T/pt unknown
- 2016-03-18 AU AU2016235495A patent/AU2016235495B2/en active Active
- 2016-03-18 HR HRP20221240TT patent/HRP20221240T1/hr unknown
- 2016-03-18 MX MX2017011978A patent/MX383647B/es unknown
- 2016-03-18 CA CA2979853A patent/CA2979853C/en active Active
- 2016-03-18 CN CN201680028306.5A patent/CN107530323B/zh active Active
- 2016-03-18 HU HUE16769437A patent/HUE060240T2/hu unknown
- 2016-03-18 SM SM20220407T patent/SMT202200407T1/it unknown
- 2016-03-18 ES ES16769437T patent/ES2928396T3/es active Active
- 2016-03-18 WO PCT/US2016/023231 patent/WO2016154039A1/en not_active Ceased
- 2016-03-18 DK DK16769437.1T patent/DK3347006T3/da active
- 2016-03-18 SI SI201631611T patent/SI3347006T1/sl unknown
-
2017
- 2017-09-18 IL IL254567A patent/IL254567B/en active IP Right Grant
-
2018
- 2018-09-21 US US16/138,509 patent/US10736901B2/en active Active
-
2020
- 2020-03-09 AU AU2020201728A patent/AU2020201728B2/en active Active
- 2020-08-07 US US16/988,586 patent/US11672805B2/en active Active
- 2020-08-20 JP JP2020139537A patent/JP2021001174A/ja active Pending
-
2022
- 2022-11-02 JP JP2022176234A patent/JP7376668B2/ja active Active
-
2023
- 2023-05-01 US US18/141,999 patent/US12433896B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7376668B2 (ja) | エチホキシンの重水素化類似体、それらの誘導体、およびそれらの使用 | |
| EP2938341B1 (en) | Heterocyclic compounds and methods of use thereof | |
| EP3157926B1 (en) | Organic compounds | |
| JP2020023496A6 (ja) | 有機化合物 | |
| EP3390374A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| JPWO2004113300A1 (ja) | 新規三環性複素環化合物 | |
| WO2007109288A2 (en) | Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use | |
| EP2007741A1 (en) | Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use | |
| CN106986859B (zh) | 吲哚衍生物及其用途 | |
| US20240189316A1 (en) | Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism | |
| CN106674207A (zh) | 取代的芳基杂芳基化合物及其用途 | |
| WO2002069951A2 (en) | Composition containing a nefazonoid such as nefazodone and a serotonin-inhibitor such as fluoxetine |